Apersys AG

Apersys AG is a Swiss medtech company focused on advanced organ preservation technology. Its mission is to increase the number of transplantable organs and enhance patient outcomes in organ transplantation. The company originated from the Liver4Life project, a collaboration involving ETH Zurich, the University Hospital Zurich, and the Wyss Translational Center Zurich. Apersys has developed a long-term normothermic perfusion platform that can preserve organs, particularly livers, outside the human body for up to 7 days, significantly exceeding the standard preservation times. The core product, the Perfusion System, creates an ideal physiological environment to maintain and recover livers that may not be suitable for transplantation. This innovative technology has shown promising results in preclinical and first-in-human studies, with a notable achievement in 2021 when the first patient received a liver transplant after 3 days of organ perfusion. Apersys has also earned the FDA Breakthrough Device Designation in 2023, highlighting the clinical significance of its technology. The company aims to improve the availability and quality of donor organs, benefiting patients in need of liver transplants.

• Employees 13
• Founded 2024